Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C24H38N4O4S |
Molecular Weight | 478.648 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C(=O)CC[C@]13CC[C@@H](C)[C@@]2(C)[C@@H](C[C@@](C)(CC)[C@@H](O)[C@@H]3C)OC(=O)CSC4=NN=C(N)N4
InChI
InChIKey=FMHQJXGMLMSMLC-WBUYAQKGSA-N
InChI=1S/C24H38N4O4S/c1-6-22(4)11-16(32-17(30)12-33-21-26-20(25)27-28-21)23(5)13(2)7-9-24(14(3)19(22)31)10-8-15(29)18(23)24/h13-14,16,18-19,31H,6-12H2,1-5H3,(H3,25,26,27,28)/t13-,14+,16-,18+,19+,22-,23+,24+/m1/s1
Molecular Formula | C24H38N4O4S |
Molecular Weight | 478.648 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Azamulin [14-O-(5-(2-amino-1,3,4-triazolyl)thioacetyl)-dihydromutilin] is an azole derivative of the pleuromutilin class of antiinfectives. Azamulin is a selective, irreversible inhibitor of cytochrome P450 (CYP) 3A isoforms (IC50 values range from 26 to 240 nM for CYP3A4 and CYP3A4/5 from different sources). It is at least 50-fold less potent against CYP2J2 and 100-fold less effective against all other CYP isoforms. Azamulin potently blocks the hydroxylation of testosterone and midazolam by CYP3A4. Azamulin exhibited remarkable
antibacterial activity against all Gram-positive pathogens including
MRSA, PRSP, and VRE, except for E. faecalis.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3491 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14709627 |
6.6 µM [IC50] | ||
Target ID: CHEMBL2364675 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14709627 |
0.026 µM [IC50] | ||
Target ID: CHEMBL3019 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14709627 |
0.38 µM [IC50] | ||
Target ID: CHEMBL3341582 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14709627 |
0.34 µM [IC50] | ||
Target ID: CHEMBL347 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14709627 |
|||
Target ID: CHEMBL352 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14709627 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18330977
Lethal S. aureus (MSSA) systemic infection model in mice: ED50 of 13.3 mg/kg, po
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14709627
Preincubation of 4.8 uM and 9.6 uM azamulin (concentrations 20 and
40 times the IC50, respectively) for 5 min with a CYP3A-enriched
Human Liver Microsomes (HLM) pool in the presence of NADPH prior to a 1:20 dilution into a
testosterone reaction mix eliminated more than 90% of the testosterone
6beta-hydroxylase activity compared with preincubation in the absence
of NADPH.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:48:25 GMT 2023
by
admin
on
Fri Dec 15 15:48:25 GMT 2023
|
Record UNII |
875AQ866X1
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C52588
Created by
admin on Fri Dec 15 15:48:25 GMT 2023 , Edited by admin on Fri Dec 15 15:48:25 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
16072188
Created by
admin on Fri Dec 15 15:48:25 GMT 2023 , Edited by admin on Fri Dec 15 15:48:25 GMT 2023
|
PRIMARY | |||
|
5745
Created by
admin on Fri Dec 15 15:48:25 GMT 2023 , Edited by admin on Fri Dec 15 15:48:25 GMT 2023
|
PRIMARY | |||
|
C83608
Created by
admin on Fri Dec 15 15:48:25 GMT 2023 , Edited by admin on Fri Dec 15 15:48:25 GMT 2023
|
PRIMARY | |||
|
76530-44-4
Created by
admin on Fri Dec 15 15:48:25 GMT 2023 , Edited by admin on Fri Dec 15 15:48:25 GMT 2023
|
PRIMARY | |||
|
Azamulin
Created by
admin on Fri Dec 15 15:48:25 GMT 2023 , Edited by admin on Fri Dec 15 15:48:25 GMT 2023
|
PRIMARY | |||
|
100000086890
Created by
admin on Fri Dec 15 15:48:25 GMT 2023 , Edited by admin on Fri Dec 15 15:48:25 GMT 2023
|
PRIMARY | |||
|
CHEMBL2103760
Created by
admin on Fri Dec 15 15:48:25 GMT 2023 , Edited by admin on Fri Dec 15 15:48:25 GMT 2023
|
PRIMARY | |||
|
C489644
Created by
admin on Fri Dec 15 15:48:25 GMT 2023 , Edited by admin on Fri Dec 15 15:48:25 GMT 2023
|
PRIMARY | |||
|
875AQ866X1
Created by
admin on Fri Dec 15 15:48:25 GMT 2023 , Edited by admin on Fri Dec 15 15:48:25 GMT 2023
|
PRIMARY | |||
|
DTXSID301046434
Created by
admin on Fri Dec 15 15:48:25 GMT 2023 , Edited by admin on Fri Dec 15 15:48:25 GMT 2023
|
PRIMARY | |||
|
SUB05633MIG
Created by
admin on Fri Dec 15 15:48:25 GMT 2023 , Edited by admin on Fri Dec 15 15:48:25 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |